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Non-Hodgkin lymphomas arising from mature post-thy-
mic T cells (T-NHL) encompass biologically heteroge-
neous malignancies with a dismal prognosis (1, 2).
Patients with histotypes such as peripheral T-cell lym-
phoma not otherwise specified (PTCL-NOS), kinase-neg-
ative anaplastic large cell lymphoma (ALK-negative
ALCL), angioimmunoblastic T-cell lymphoma, and Sez-
ary syndrome (SS) experience early disease recurrence
with 5-yr overall survival rates rarely exceeding 40%,
also because of the lack of effective salvage strategies (1–
3). While the biologic basis of T-NHL aggressiveness is
under extensive research, investigation into novel active
agents remains a critical need, especially in the setting of
stem cell transplantation ineligibility ⁄ failure and end-
stage disease (2, 4).
Fotemustine is a third-generation chloroethylnitrosou-
rea displaying a significant clinical efficacy in highly
chemoresistant cancers such as disseminated melanoma
and primary or metastatic brain tumors (5–9). While sec-
ond-generation nitrosoureas have been incorporated into
standard and high-dose salvage regimens for NHL,
including T-cell subtypes (10–13), the activity of fotemus-
tine in lymphoma has been poorly explored, despite its
lower hepatic and renal toxicity, as compared to conge-
ner agents, and several more favorable pharmacody-
namic properties (14, 15). First, the presence of a
phosphoalanine carrier group renders fotemustine more
lipophilic because its octanol ⁄water partition coefficient
results within the optimal lipophilicity interval, differ-
ently from both carmustine and lomustine (16, 17).
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Second, preclinical studies on rat and human tissues have
shown that intracellular penetration of fotemustine is
superior to that of carmustine (18, 19). Third, studies
have documented that fotemustine is cleared 2–5 times
more slowly than carmustine from tumor tissues (17–19).
The higher lipophilic properties, the more efficient tissue
distribution, and slower elimination of fotemustine from
tumor tissues, as compared to other nitrosoureas, might
provide a preclinical rationale for testing this drug in
chemorefractory lymphomas.
Because normal and malignant T cells express a low
level of O6-alkylguanine-DNA alkyltransferase (AGT)
and of O6-methylguanine-DNA methyltransferase
(MGMT) (20, 21), two DNA repair enzymes implicated in
cellular resistance to nitrosureas, and specifically to fote-
mustine (22–25), we speculated that alkylator-refractory
T-NHL could represent a proper setting to explore the
potential clinical activity of this newer nitrosourea deriva-
tive. Here, we report the first evidence ever that fotemus-
tine is able to induce substantial clinical responses in
patients with post-thymic T-cell malignancies.
Methods
Five consecutive patients (three men, two women; age
range, 54–77 yr) with biopsy-proven recurrent T-NHL
[ALK-negative ALCL (n = 2), PTCL-NOS (n = 1), and
SS (n = 2)] were accrued into a named-patient program
with single agent fotemustine. Treatment consisted of
fotemustine 120 mg ⁄m2, as a 1-h intravenous infusion, at
day 1 every 3 wk until progression, unacceptable toxicity,
or a maximum of eight administrations. The program
was approved by the Internal Pharmaceutical Review
Board, and after obtaining written informed consent
from patients, fotemustine (Muphoran, S10036; Servier,
Neuilly-sur-Seine, France) was purchased from Italfar-
maco S.p.A. (Milan, Italy). Within 2 wk prior to treat-
ment, patients underwent a complete disease staging
including bone marrow (BM) biopsy, computer-assisted
tomography (CT), 18F-fluoro-deoxy-glucose (18F-FDG)
positron emission tomography (PET), and echotomo-
graphic assessment of superficial disease sites. Skin
involvement was assessed through the modified Severity
Weighted Assessment Tool (mSWAT) (26). Levels of sol-
uble interleukin-2 receptor (sIL-2R) were determined on
cryopreserved serum samples obtained prior to fotemus-
tine treatment. Primary prophylaxis with trimethoprim-
sulfamethoxazole and valacyclovir was mandatory, while
granulocyte colony-stimulating factor recommended only
in case of grade 3 ⁄ 4 neutropenia. Response evaluation
was planned every two courses, interim restaging after
four courses, and final assessment at the completion of
treatment, according to the International Workshop (27)
and to ISCL ⁄EORTC criteria (28).
Case report
Baseline clinical features and treatment outcomes for all
five patients are summarized in Tables 1 and 2, respec-
tively. All were stage IV disease; most of them presented
with a poor performance status and had received three
prior lines of therapy [CHOP or CHOP-like chemotherapy
(n = 3), gemcitabine-based regimens (n = 5), platinum
and ifosfamide containing regimens (n = 4), newer agents
including vorinostat (n = 1), bortezomib (n = 2), and
alemtuzumab (n = 1)]. The treatment was given on an
outpatient basis, and the related complications never
required hospitalization. A total of 28 infusions of fote-
mustine were delivered. Overall, treatment duration was
8–28 wk, and the cumulative dose ranged from 280 to
880 mg ⁄m2, with a median dose intensity [defined as actu-
ally delivered dose (mg ⁄m2 ⁄wk) divided by the planned
dose (mg ⁄m2 ⁄wk)] of 79% for the first four courses. A
dose reduction of fotemustine to 75% was needed, after 1-
wk delay, in patients 2 (3rd course), in patient 3 (4th
course), and in patient 4 (from course 3rd to 5th). All
patients were evaluable for response, and none of them
had to discontinue treatment owing to excessive toxicity:
two had a major response, one complete (patient 1) and
one partial (patient 4), and two others achieved disease
stabilization (patients 3 and 5), while only one progressed
following an early minor response (patient 2).
A complete response (CR) was achieved in patient 1.
He had a stage IVB chemorefractory end-stage SS with
high blood burden of CD4+ ⁄CD7 tumor cells, BM
involvement, multicentric nodal disease (bilateral axillary
and inguinal, intercavoaortic, lomboaortic) (Fig. 1A) and
highly symptomatic disseminated desquamating erythro-
derma with patch-like skin lesions, palmar fissuring and
intense, disabling itching. Skin disease completely
reverted after the first two doses of fotemustine, while a
residual PET-positive left inguinal adenopathy was still
documented at interim restaging. A total regression of all
18F-FDG uptakes and a complete clearance of tumor T
cells from blood and BM were documented by the end
of treatment (eight courses) leading to a CR (Fig. 1A),
which was maintained up to +240 d.
A partial response was achieved in patient 4. She suf-
fered from a refractory ALK-negative ALCL with multi-
ple skin-infiltrating nodules at the scalp and the right
frontal-zygomatic area, together with a painful bulky
swelling at right neck infiltrating cervical lymph nodes,
parotid, and soft tissue planes. A complete regression of
cutaneous involvement was achieved within 1 month from
starting treatment; a maximum of 65% sharp reduction
occurred, after three courses, in the sum of the products
of the greatest diameters in the cervical ⁄parotid gross
lesion with an impressive decrease in the 18FDG uptake
intensity and extension at PET scanning (Fig. 1B), as
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compared with baseline. Response persisted for 4 months,
and thereafter, a progression was documented at day 165.
Disease stabilizations were observed in patients 3 and
5. Patient 3 had a chemorefractory ALK-negative ALCL
with BM involvement and widespread nodal disease (lat-
erocervical, retroclavear, subclavear, axillary, mediasti-
nal, intercavoaortic, lomboaortic, splenic hilum, iliac,
obturator, and inguinal) complicated by massive ascites.
Treatment with fotemustine reduced nodal bulks and
abrogated the need for paracentesis for about 3 months.
Patient 5 had a multicentric nodal relapse of a PTCL-
NOS together with a quickly onset leukemic
(CD2+ ⁄CD3+ ⁄CD4+ ⁄CD5+ ⁄CD7+) hypercytosis
(303 · 109 ⁄L). He achieved a long-lasting control of
nodal and leukemic evolution, while receiving treatment,
for an overall period of 144 d, as long as T cells contin-
ued to decline in the absence of any disease-related
symptoms, cytopenia, and toxicity (Fig. 1C). Subse-
quently, a further rise in lymphoid neoplastic cells up to
73 · 109 ⁄L, paralleled by a drop in platelets count, down
to below 20 · 109 ⁄L, impelled for a therapeutic diver-
sion.
Only a minor response occurred in patient 2; he had a
SS with large fungating skin lesions at posterior trunk,
multiple plaques at left wrist, face, and scalp, and ery-
thematous patches at the left thigh together with nodal
and leukemic (CD2+ ⁄CD3) ⁄CD4+, CD5+, CD7),
CD8)) disease. Three fotemustine courses were delivered
to this patient. Following the early rapid fainting of skin
lesions, accompanied by an impressive resolution of cuta-
neous symptoms, he developed a full-blown disease pro-
gression shortly afterward the third course. Differently
from patient 1, also affected by SS, who achieved a CR,
this patient had high-burden tumoral lesions, a higher
mSWAT score, and a more aggressive disease behavior
as also indicated by elevated LDH values and a high
serum level of sIL-2R (29, 30).
Toxicity of treatment, as assessed according to the
NCI Common Terminology Criteria for Adverse Events
(version 3.0), was mainly hematological. Grades 3 and 4
thrombocytopenia occurred in three patients with a total
of five courses requiring transfusion support. Grade 4
anemia required transfusions in two patients for overall
four courses. Febrile neutropenia requiring intravenous
antimicrobial therapy complicated three courses. A
destructive infection of the deep skin and tissues at back
chest wall, sustained by Gram-positive cocci and anaero-
bic clostridia, occurred in patient 2.
Discussion
Case reports presented herein provide the first evidence
that fotemustine can achieve clinical responses in che-
morefractory T-NHL. Two major responses (one com-
plete) and two protracted disease stabilizations were
recorded in four of five treated patients, all with highly
unfavorable disease, recurring after alkylators and gem-
citabine (i.e., two hallmarks of T-NHL therapy) and, in
most cases, CHOP therapy or new agents such as bort-
ezomib, vorinostat, and alemtuzumab. Several new
agents are being actively explored in advanced T-NHL
including, among others, folate antagonists such as pra-
Table 2 Pretreatment disease-status, response, and adverse events
N
Age ⁄
sex Histology
Prior therapy
n (type)
Response to
prior therapy
Fotemustine
n of courses
Best
response
Time
to best
response (d)1
Time to
progression
(d)2 Status
CTCAE v3.0
toxicity
1 54 ⁄M Sezary
syndrome
3 (CHOP,
gemcitabine,
vorinostat)
Refractory 8 CR 150 240+ Alive
in CR
G3 thrombocytopenia
2 78 ⁄M Sezary
syndrome
2 (GIFOX; VCG) Refractory 3 PD – 48 Died
for PD
G4 anemia
G4 infection
G4 platelets
3 57 ⁄ F ALCL
ALK-neg
3 (CHOP,
DHAP, GIFOX)
Refractory 4 SD 42 86 Died
for PD
G4 thrombocytopenia
G3 febrile neutropenia
G4 anemia
4 74 ⁄ F ALCL
ALK-neg
3 (CHOEP,
GIFOX, VCG)
Refractory 6 PR 54 165 Died
for PD
G3 neutropenia
G3 infection
5 77 ⁄M PTCL-nos 2 (GIFOX,
alemtuzumab)
Relapse 7 SD 68 144+ Alive
in PD
None
M, male; F, female; ALCL, anaplastic large T-cell lymphoma; PTCL-nos, peripheral T-cell lymphoma not otherwise specified; CHOP, cyclophospha-
mide, adriamycin, vincristine, prednisone; CHOEP, cyclophosphamide, adriamycin, vincristine, etoposide, prednisone; GIFOX, gemcitabine, ifosfa-
mide, oxaliplatin; VCG, bortezomib, cyclophosphamide, gemcitabine; DHAP, dexamethasone, cytarabine, cisplatin; CHOEP, cyclophosphamide,
adriamycin, vincristine, etoposide, prednisone; CR, complete response; PR, partial remission; SD, stable disease; PD, progression of disease;
CTCAE v3.0, Common Terminology Criteria for Adverse Events version 3.0.
1From day of the 1st dose of treatment to documentation of best response.
2From day of the 1st dose of treatment to documentation of progression.
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latrexate, monoclonal antibodies, signaling inhibitors,
and immunomodulatory agents (31). In the absence of a
recognized gold standard for salvage and even upfront
treatment for T-NHL (4, 31), we identified fotemustine,
as a possible therapeutic option for our patients, owing
to its pharmacodynamic advantages over other nitrosou-
reas (16–18), the low expression of AGT and MGMT in
T-cell tumors (20, 21), and its favorable toxicity profile
in pretreated patients (32).
Thus far, very few studies have addressed the role of
fotemustine in hematological malignancies, with data
published only for recurrent multiple myeloma (33, 34).
More recently, we demonstrated that high doses of fote-
mustine (300 mg ⁄m2) can be safely incorporated into an
active new conditioning regimen (fotemustine, etoposide,
cytarabine, and melphalan; FEAM), for autologous stem
cell transplant (35). The FEAM regimen, as applied to
84 patients with lymphoma, favorably compared with
the classical BEAM (carmustine, etoposide, cytarabine,
and melphalan) conditioning in terms of activity and tox-
icity and was able to convert pretransplant PR into CR
in 25 of 32 patients (78%) (35), including four of seven
PTCL cases (Pinto A, unpublished observations). Inter-
estingly, the FEAM regimen was devoid of pulmonary
toxicity, as compared to the carmustine-containing
BEAM, and displayed a lower rate of renal and hepatic
toxicities (14, 35).
Noteworthy, fotemustine induced a fast and impres-
sive activity on cutaneous lesions in our patients along
with a rapid resolution of erythroderma and severe itch-
ing. In this respect, intravenous fotemustine may be of
value in the palliative treatment for lymphoma-related
refractory cutaneous symptoms. Whether this effect
might be ascribed to a preferential accumulation ⁄ reten-
tion of the agent in the skin, as suggested by the highly
lipophilic features (16) and significant activity of fote-
mustine in cutaneous melanoma (6), remains to be estab-
lished.
Our patients with T-NHL were treated with a schedule
differing from the treatment usually adopted for mela-
noma and brain tumors, i.e., 300 mg ⁄m2 over an 8-wk
period (100 mg ⁄m2 on days 1, 8, 15 to be followed, after
a 5-wk rest, by 100 mg ⁄m2 at a 3-weekly interval) (6, 8).
Owing to the rapid regrowth rate of tumors in our
patients and the significant amount of previous myelo-
toxic therapy, we reasoned that fixing fotemustine dose
to 120 mg ⁄m2 at a 3-weekly interval could have realized
a dose intensity able to control disease burden and kinet-
ics, without a heavy load of early myelotoxicity. As a
matter of fact, this allowed delivery of a sufficient num-
ber of courses at a median dose intensity approaching
80% with an acceptable hematological toxicity and with-
out drug-related serious adverse events.
Overall, our report indicates that fotemustine is active
in end-stage T-NHL and represents an agent worth of
being further investigated in such disease setting. Beyond
confirming our preliminary evidences, it would be of
interest to study the impact of AGT expression and
MGMT promoter methylation status on fotemustine
activity in T-cell lymphomas. Expression of both these
DNA repair enzymes was shown to predict sensitivity to
fotemustine in glioma and melanoma (20–24). These
studies should also be aimed at defining the optimal
A
B
C
Figure 1 (A) Pretreatment nodal 18F-FDG uptakes (bilateral axillary
and inguinal, intercavoaortic, lomboaortic) completely regressed after
completion of fotemustine treatment in patient 1. (B) Changes
18F-FDG uptake of a cervical-parotid gross tumor lesion after three
courses of fotemustine in patient 4. (C) The control of the leukemic
(CD3+ ⁄CD4+) hypercytosis exerted by fotemustine in patient 5.
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schedule of fotemustine for T-cell malignancies, which
may differ from that used for melanoma and brain
tumors.
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